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Abstract
The HIV/AIDS pandemic is a major global health threat and understanding the detailed molecular mechanisms of HIV
replication is critical for the development of novel therapeutics. To replicate, HIV-1 must access the nucleus of infected cells
and integrate into host chromosomes, however little is known about the events occurring post-nuclear entry but before
integration. Here we show that the karyopherin Transportin 3 (Tnp3) promotes HIV-1 integration in different cell types.
Furthermore Tnp3 binds the viral capsid proteins and tRNAs incorporated into viral particles. Interaction between Tnp3,
capsid and tRNAs is stronger in the presence of RanGTP, consistent with the possibility that Tnp3 is an export factor for
these substrates. In agreement with this interpretation, we found that Tnp3 exports from the nuclei viral tRNAs in a RanGTP-
dependent way. Tnp3 also binds and exports from the nuclei some species of cellular tRNAs with a defective 39CCA end.
Depletion of Tnp3 results in a re-distribution of HIV-1 capsid proteins between nucleus and cytoplasm however HIV-1
bearing the N74D mutation in capsid, which is insensitive to Tnp3 depletion, does not show nucleocytoplasmic
redistribution of capsid proteins. We propose that Tnp3 promotes HIV-1 infection by displacing any capsid and tRNA that
remain bound to the pre-integration complex after nuclear entry to facilitate integration. The results also provide evidence
for a novel tRNA nucleocytoplasmic trafficking pathway in human cells.
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Introduction
Akin to other viruses [1], after cell-receptor mediated entry into
the cell, HIV-1 undergoes an uncoating step by shedding its capsid
core [2,3], which is constituted by approximately 1,500 capsid
proteins (CA) arranged in a hexameric lattice [4]. This step is
incompletely understood yet it is important to maintain optimal
infectivity [3,5,6]. If uncoating of the viral core takes place too
early, infectivity is impaired as observed with viral mutants having
unstable capsid cores or in the presence of certain members of the
TRIM protein family [5,7,8]. If the virus uncoats too late or
incompletely, infectivity is also impaired [5,9]. Interestingly,
proper uncoating of the viral core, which is thought to take place
in the cytoplasm of infected cells during reverse transcription
[6,10], can also influence later events such as nuclear entry and
integration [9,11].
Changes in CA have been shown to impact on HIV-1 nuclear
import and infection of non-dividing cells in several ways.
Substitution of HIV-1 CA with MLV CA impairs HIV-1 ability
to infect non-dividing cells [12]. This CA substitution makes HIV-1
phenotypically similar to the murine leukemia virus (MLV), which
cannot efficiently infect non-dividing cells and maintains relatively
large amounts of CA associated with its reverse transcription
complex (RTC) [13]. HIV-1 CAmay determine which components
of the nuclear pore complex (NPC) are preferentially used for
infection, because specific mutations in CA make the virus less
dependent on NUP153 and more dependent on NUP155 [14].
Furthermore, CA influences incorporation of certain tRNAs species
into the viral particle, which promote HIV-1 entry into the nucleus,
presumably by recruiting the intracellular viral complex into the so
called tRNA retrograde transport pathway [15,16].
CA also impacts on post-nuclear entry events. HIV-1 mutants
that maintain larger amounts of CA associated with their RTCs
and pre-integration complexes (PICs) integrate less efficiently [9].
Furthermore, the restriction factors TRIMcyp and TRIM19,
which bind to CA, can block post-nuclear entry steps required for
efficient integration [17]. This evidence supports a functional link
between CA, uncoating, nuclear import and integration [9,11,17],
however a unifying picture is lacking and little is known of the
events taking place between HIV-1 nuclear entry and integration.
Interestingly, recent high throughput screenings showed that
Transportin 3 (Tnp3) (Gene ID: 23534) is a host factor critical for
some events occurring at or shortly after HIV-1 nuclear import
[18,19,20,21]. Tnp3 belongs to the importin ß superfamily of
nuclear transport receptors that bind RanGTP at their N-termini
[22] and participate in nucleocytoplasmic transport of proteins
and nucleic acids by interacting with specific FG-repeats present in
many nucleoporins, the constituents of the NPC [23].
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Members of the importin ß superfamily can act as nuclear import
or export receptors (or both) depending on whether they bind or
release the cargo in the presence of RanGTP. Nuclear import
receptors bind their cargos in the cytoplasm and release them in the
nucleus upon binding to RanGTP, whereas nuclear export receptors
bind their cargos in the nucleus in complex with RanGTP and
dissociate from them in the cytoplasm upon hydrolysis of RanGTP
[24]. In the nucleus, RanGDP in enzymatically converted into
RanGTP by the regulator of chromatin condensation-1 (RCC1), a
chromatin-bound guanine nucleotide exchange factor, whereas on
the cytoplasmic face of the NPC RanGTP is hydrolyzed into
RanGDP by the Ran GTPase-activating protein (RanGAP1) and
RanBP1 [24]. Hence a concentration gradient of RanGTP (high in
the nucleus and low in the cytoplasm) is maintained across th nuclear
envelope, providing directionality to nucleocytoplasmic trafficking.
We have investigated the role of Tnp3 in HIV-1 infection and
found that it is important for the completion of a post nuclear-
entry step. We show that Tnp3 binds to CA and tRNA species
present in the viral particle in a RanGTP-dependent way,
facilitates their nuclear export and may promote a maturation
step of the PIC inside the nucleus required for efficient integration.
Remarkably, we found that Tnp3 is also an export factor for
certain cellular tRNA species lacking a complete 39 CCA end.
Results
Tnp3 is required for efficient HIV-1 integration
We wanted to investigate the role of Tnp3 in cell types relevant
to HIV-1 infection, including macrophages and CD4+ T-cells. To
this end, Tnp3 was depleted in human embryonic stem (ES) cell-
derived macrophages [25] by lentiviral delivery of an shRNA
targeting Tnp3 mRNA or the DsRed mRNA as control [26] and
cells were infected four days later with an HIV-1 vector bearing
the green fluorescent protein expression cassette (HIVGFP). Levels
of Tnp3 appeared to be low in differentiated macrophages and
even a fairly modest depletion of Tnp3 resulted in ,10-fold
inhibition of HIV-1GFP infection (Figure 1A-C). A greater
depletion of Tnp3 corresponded to a greater block to HIVGFP
infection (Figure 1A-C). Similar results were obtained in blood-
derived macrophages (Figure 1D, 1E), in agreement with Christ et
al. [20]. Next, we depleted Tnp3 in CD4+ Jurkat T-cells using
a MLV vector to deliver an shRNA targeting Tnp3 mRNA.
Relative to macrophages, HIV-1GFP infection was modestly (,3
fold) but consistently inhibited in Jurkat Tnp3 knock-down (KD)
cells, despite effective Tnp3 depletion (Figures S1A, S1B). We also
depleted Tnp3 in HeLa cells by using two different siRNAs.
Depletion of Tnp3 in HeLa cells resulted in ,7 fold inhibition of
infection with the best siRNA (Figure 2A, 2B) in agreement with
previous reports [18,20]. Hence Tnp3 supports efficient HIV-1
infection in relevant target cells although different cell types might
require different levels of Tnp3 to that end.
We used HeLa cells, which can be grown in sufficiently large
quantity and showed a robust phenotype, to examine in more
detail which step of the HIV-1 life cycle was affected by depletion
of Tnp3 (Figure 2). Reverse transcription of the viral RNA genome
was not impaired in HeLa Tnp3 KD cells, however we detected
10 fold less viral DNA one week post-infection (Figure 2C),
suggesting that viral nuclear import or integration (or both) were
defective. To investigate viral nuclear entry, levels of 2LTRs
circular DNA (a viral DNA form that is generated by end-ligation
inside the nucleus) [27] were measured by TaqMan qPCR at 24 h
and 48 h post-infection. Similar amounts of 2LTR circular DNA
were detected in control and KD cells (Figure 2D). Infected cells
were also fractionated and the distribution of viral DNA in the
cytoplasm and nucleus was examined by TaqMan qPCR. A
similar distribution of viral DNA in the nuclear and cytoplasmic
fractions of Tnp3 KD and control cells suggested that viral
nuclear import was not defective (Figure 2E). The quality of the
fractionation was controlled two fold. First, 2LTR circular viral
DNA was enriched .20 fold in the nuclear fractions, consistent
with the notion that viral DNA is circularized inside the nucleus
[27] (Figure 2F). Second, the distribution of spliced cyclophilin A
mRNA in each fraction showed that contamination of nuclei with
cytoplasmic material was ,5% [26] (Figure 2G). This result also
indicated that fractionated nuclei were mostly devoid of the
external nuclear envelope layer, which is contiguous with the ER.
To test if viral DNA could be bound to the nuclear envelope, we
fractionated infected cells in the presence of DNAse I beads.
Whereas DNAse beads could digest in part viral DNA in the
cytoplasm, viral DNA in the nuclear fraction was unaffected,
suggesting that it was inside the nuclei and protected from
digestion (Figure S2). Since viral nuclear import was not
significantly inhibited, we next measured integration by Alu-
PCR Taqman qPCR. We found that the amount of integrated
viral DNA was approximately 10 fold lower in Tnp3 KD cells
compared to control cells [28,29] (Figure 2H). Similar data were
obtained with a near full length HIV-1 clone containing all
accessory proteins (HIV-1LAIDenv) [12] (Figure S3). Although the
block to HIV-1GFP infection was modest in Jurkat Tnp3 KD cells,
we found that integration was the only step significantly inhibited
in these cells, consistently with the results obtained in HeLa cells
(Figure S1). These results showed that Tnp3 is required for a post-
nuclear entry step leading to efficient integration.
Tnp3 binds to CA and viral tRNAs
Tnp3 was shown to bind to HIV-1 integrase (IN), but the
biological relevance of this interaction is uncertain [19,20]. To
investigate if Tnp3 bound to other viral elements in addition to IN
and to gain a greater understanding of its function, purified virus
was used in pull down assays with recombinant Tnp3 in the
presence or absence of the RanQ69L-GTP mutant. The
RanQ69L point mutant is hydrolyzed to the GDP form with a
kinetic several orders of magnitude slower than wild type RanGTP
[30], making it more suitable for pull down assays. Addition of
RanGTP to the in vitro binding assays is critical to understand if the
nuclear transport receptor acts as an import or an export factor for
Author Summary
HIV-1, the causative agent of AIDS, is a virus that enters the
nucleus of infected cells and must integrate its genome
into the host cell DNA. Here we show that efficient HIV-1
integration depends on a host cell factor called Transportin
3. We also show that Transportin 3 can export out of the
nucleus the viral capsid proteins and viral transfer RNAs
(tRNAs) and that this activity is important for HIV-1
integration. We propose that Transportin 3 facilitates a
maturation process inside the nucleus by removing
remaining capsid proteins and tRNAs still bound to the
virus. The mature viral complex, free of any bulky
component, can then more easily integrate. Transportin
3 also export certain cellular tRNAs out of the nucleus,
presumably as a way to control cell metabolism. By
feeding into this tRNA shuttling pathway, HIV-1 can
complete its life cycle. Our work sheds new light into the
biology of HIV-1 and points to the existence of a new
pathway in human cells to shuttle certain tRNAs between
nucleus and cytoplasm.
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the specific cargo and adds an important element of specificity to
the assay.
Viral stocks were prepared from stable HIV-1 vector producer
cells pseudotyped with the amphotropic envelope [31], purified
through two sucrose gradients and analyzed by SDS-PAGE and
silver staining. This procedure allowed visualization of several viral
proteins including Env, capsid (CA) and matrix (MA). tRNAs
incorporated into viral particles [32] were also clearly visible as the
typical yellowish band migrating at ,20 kDa (Figure 3A). Pull-
down assays were performed with virus particles mildly disrupted
by gentle sonication in the absence of detergents to limit the
damage to viral cores. Viral tRNAs and CA bound to Tnp3 with
greater affinity in the presence of RanGTP (Figure 3B), implying
that Tnp3 might be an export factor for these molecules [33]. Next
we generated several Tnp3 deletion mutants (see below) and found
that a mutant lacking the last C-terminal 98 residues bound both
viral tRNAs and CA less well, suggesting that these viral
components may recognize the same Tnp3 domain (Figure 3C).
To confirm the specificity of the interaction between Tnp3 and
CA, we performed parallel pull-down assays with wild type Tnp3
with or without RanGTP, the C-term deleted Tnp3 and Exportin-
t (Figure 3D). Exportin-t (Xpo-t) is the main tRNA export receptor
Figure 1. Tnp3 supports HIV-1 infection in human macrophages. (A) HuES-2 derived macrophages were transduced with two different doses
of a lentivirus vector delivering an shRNA against human Tnp3 mRNA, or a control shRNA against dsRed mRNA and infected with a fixed amount of
HIVGFP vector 96 hours later. Five days after infection with the HIVGFP vector cells were visualized by confocal microscopy. (B) ImageJ software was
used to calculate the fluorescence intensity per cell relative to un-infected cells (zero value). At least 100 cells per field were counted. Average6 SD of
triplicate experiments are shown. (C) Knockdown of Tnp3 was demonstrated by Western blotting (upper panel). The degree of Tnp3 knockdown was
calculated by determining intensities of Tnp3 bands relative to actin bands using ImageJ software (lower panel). (D) A fixed amount of HIVGFP vector
was used to infect blood-derived macrophages previously transduced with the shRNA lentiviral vector as described in (A). GFP-positive cells were
visualised using confocal microscopy and infectious units calculated by counting the number of GFP+ cells per well. Average values6 SD of triplicate
experiments are shown. (E) Knockdown of Tnp3 was demonstrated in blood-derived macrophages by Western blotting (upper panel). The degree of
Tnp3 knockdown was calculated by determining intensities of Western blot bands using ImageJ software (lower panel).
doi:10.1371/journal.ppat.1002194.g001
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in mammalian cells and binds tRNAs with high affinity in the
presence of RanGTP [34,35,36,37]. We confirmed that Tnp3
binds CA and tRNAs with higher affinity in the presence of
RanGTP and that the C-term deleted Tnp3 did not bind
efficiently to either. Importantly, Xpo-t did bind to viral tRNAs,
consistent with the notion that viral particles contain a mix of
normal and truncated tRNAs [15], but did not bind efficiently to
HIV-1 CA (Figure 3D). The relevant tRNAs and CA gel bands
were quantified using ImageJ software analysis tool, which
confirmed the trend observed by visual inspection (Figure 3E-G).
Hence, the interaction between Tnp3 and CA is specific.
Interestingly, we were unable to detect a significant interaction
between Tnp3 and purified recombinant CA, similarly to Fv1,
TRIM5a and CPSF6 [14].
To test the biological significance of the pull down assays and
the importance of the last 98 C-term residues of Tnp3, we
Figure 2. Tnp3 is required for efficient HIV-1 infection in HeLa cells. (A) Cells were transfected with a scramble siRNA or two different siRNAs
targeting Tnp3 mRNA and analyzed by Western blot 72 h later; importin 7 (imp7) is used as a loading control. (B) Cells were transduced with HIV-1GFP
vector 48h after siRNA transfection and the number of infected cells measured by flow cytometry at the indicated time points post-infection. Average
values 6 SD of three independent experiments are shown (** p,0.01 Student’s t-test). (C) Reverse transcription and (D) accumulation of 2LTRs
circular DNA forms in Tnp3 KD cells were measured by Taqman qPCR. (E-F) Infected cells were fractionated into a cytoplasmic (cyt) and nuclear (nu)
fraction 24 h post-infection. Total viral DNA (E) and 2LTRs viral DNA forms (F) were quantified by TaqMan qPCR in each fraction. (G) RNA was
extracted from equal volumes of each fraction and reverse transcribed into cDNA. The spliced cyclophilin A mRNA was detected by PCR (500 bp) to
control for cross contamination of the fractions. M, DNA molecular weight markers. (H) DNA extracted from infected cells was subjected to Alu-LTR
TaqMan qPCR to detect integrated HIV-1 copies. Signal from the 24 h time point could not be detected consistently. Average values 6 mean
variation from two independent experiments analyzed in triplicate are shown.
doi:10.1371/journal.ppat.1002194.g002
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performed rescue experiments. A polyclonal population of 293T
cells with a stable Tnp3 KD was generated, which showed a
modest but highly reproducible defect for HIV-1 infection
(Figure 3H). The Tnp3 KD cells were then transfected with
increasing doses of a plasmid expressing wild type or the C-term
truncated Tnp3 with a point mutation to make the mRNAs
resistant to the shRNA targeting. Cells were challenged with the
HIV-1GFP vector 48h after transfection and then analyzed by flow
cytometry. Transfection of the plasmid expressing full length Tnp3
partially rescued HIV-1 vector infection; in contrast, the plasmid
expressing the C-term deleted Tnp3 showed no rescue phenotype
at all (Figure 3H). Tnp3 levels were monitored by Western
blotting: 293T cells showed a substantial KD and even a modest
recovery of Tnp3 expression above background levels was
sufficient for a partial rescue of HIV-1 vector infection
(Figure 3I). In contrast, similar levels of expression of the C-term
deleted Tnp3 did not have any effect on HIV-1GFP transduction
(Figure 3I). Hence, the last 98 residues of Tnp3 are important for
CA, tRNA binding and HIV-1GFP infection.
Tnp3 binds to cellular tRNAs
The pull down assays showed greater binding of Tnp3 to viral
tRNAs in the presence of RanGTP, suggesting that Tnp3 may be
an export factor for these molecules. We wanted to investigate this
aspect further and understand if the putative Tnp3 export activity
was limited to viral tRNAs or was broader and extended to cellular
tRNAs as well. To test if cellular tRNAs bound Tnp3 we
performed pull-down assays with high speed cytosolic extracts
Figure 3. Tnp3 binds viral tRNA and CA. (A) Purified HIV-1 vector used for pull down assays was visualized by silver staining after 15%
denaturing PAGE. Env, viral envelope glycoproteins; p24(CA), capsid proteins; p17(MA), matrix proteins. (B) Pull down assay with purified virus and
GST-Tnp3 in the presence or absence of RanQ69L-GTP. (C) Pull down assay with purified virus and GST-Tnp3 (FL) or GST-Tnp3 DC825 (DC) deletion
mutant in the presence of RanQ69L-GTP. Unlabelled bands are impurities from the Tnp3 preparations. WB p24, Western blot with an anti-capsid
antibody. (D) Pull down assay with GST-Tnp3 (FL), GST-Tnp3 DC825 (DC) or GST-Xpo-t (Xpo-t). Samples were analyzed by silver stain and by Western
blot with anti-capsid and anti-GST antibodies. (E) ImageJ quantification of tRNA and CA in pull down assays as shown in B. RanGTP increased CA
binding to Tnp3 by 2.560.5 fold in three independent experiments. (F) ImageJ quantification of pull down assays as shown in C. Values are expressed
as ratio of input versus recovered tRNAs. DC825 Tnp3 had 360.5 fold reduced binding to CA in two independent experiments. (G) tRNA titration
curve after silver staining of the SDS-PAGE gel. (H) Rescue experiment. Polyclonal populations of scramble (Scrl) or Tnp3 KD (KD) 293T cells were
transfected with plasmid DNA expressing full length (FL) Tnp3 or Tnp3 DC825 bearing a silent point mutation to make them resistant to the shRNA
effect (DC). Cells were transduced with an HIV-1GFP vector and analyzed by flow cytometry 24 hours later. Mean values 6 SD of four independent
experiments are shown; Student’s t-test was used to calculate statistical significance. (I) Western blot to detect Tnp3 expression in transfected cells.
WT, Scrl cells; FL1 and FL2, KD cells transfected with 1 mg and 2 mg Tnp3 cDNA respectively; DC1 and DC2, KD cells transfected with the same
amounts of Tnp3 DC825 cDNA. Bottom panel, quantification of the Tnp3 signal. To quantify signal in FL samples, the background from pre-existing
Tnp3 (as detected in the DC825 cDNA-transfected samples) was subtracted and all values were normalized for actin input.
doi:10.1371/journal.ppat.1002194.g003
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(HSEs), which are devoid of ribosomes and polysomes but contain
plenty of cellular tRNAs [15]. HSE was incubated with GST-
Tnp3 beads and factors bound to the beads were eluted and
analyzed by SDS-PAGE and silver staining. Several proteins in the
HSE bound non-specifically to the GST-beads and served as a
loading control but a number of other proteins specifically bound
to GST-Tnp3 beads and were selectively enriched in the presence
of RanQ69L-GTP (Figure 4A). Notably, a yellowish band
migrating at ,20 kDa was also specifically recovered in the
Tnp3 pull downs and clearly enriched in the presence of
RanQ69L-GTP (Figure 4A). This band was strikingly similar to
the tRNAs band that we previously observed in HSE fractions
active in HIV-1 RTC nuclear import [15], hence we purified
nucleic acids in the eluted fractions and re-analyzed the samples in
a long denaturing urea gel, which was stained with a fluorescent
dye specific for nucleic acids. Using this procedure we could
confirm that the band observed by silver staining was indeed
tRNAs (Figure 4B).
Certain tRNA species lacking a complete 39 CCA end have
been previously shown to promote HIV-1 nuclear import [15]. We
therefore asked whether the same tRNAs would bind Tnp3 in the
presence of RanGTP. To this end we performed pull down assays
with in vitro synthesized tRNAlys1,2 lacking the 39 CCA tail
(hereafter called G2). To control for specificity, a mutant G2
tRNA with a 39 TTT tail replacing the normal CCA tail (hereafter
called m2) was tested in parallel and assays were performed in the
presence of RanGTP or RanGDP. Tnp3 bound G2 tRNA with
greater affinity in the presence of RanGTP than RanGDP, in
agreement with the results obtained with cellular tRNAs.
Interestingly, the m2 mutant bound Tnp3 less efficiently than
G2, suggesting that the 39 tail may modulate recognition
(Figure 5A and 5B left panel).
tRNA regions required for binding to Tnp3
To explore the role of the 39 tail and to map other tRNA
regions important for Tnp3 binding, we generated a panel of
tRNA mutants and examined their ability to bind Tnp3 in pull
down assays (Table 1, Figures 5 and 6). As a control, selected
mutants were also tested for their ability to bind Xpo-t, which has
rather stringent structural requirements for tRNA recognition,
including a full 39 CCA tail [34,35,36,37]. Remarkably, a G2
variant having a complete 39 CCA end (mutant m2a) bound Tnp3
poorly (Figure 5A and 5B, middle panels). In contrast, the m2a
tRNA bound well to Xpo-t (Figure 5A and 5B, right panels). A G2
tRNA variant with the U55A point mutation in the T-loop region
(m5) also showed weaker binding to Tnp3 than G2 (Figure 6). This
mutation disrupts the interaction between nucleotides U55-G18,
which is important for correct tRNA 3D folding [38], suggesting
that a certain degree of tertiary structure integrity is necessary.
This was confirmed by generating the U55G/G18U double
mutant (m6) to restore the interaction between nucleotides 55 and
18, which indeed showed an improved binding to Tnp3, if
compared to m5 (Figure 6). Single point mutation m10, which
disturbed the T-loop conformation, did not significantly impact on
binding to Tnp3 while the affinity to Xpo-t was decreased
(Figure 6). These observations suggested that tRNA binding to
Figure 4. Tnp3 binds cellular tRNAs. (A) Pull down assays with high-speed cytosolic extracts (HSE) and GST-Tnp3 in the presence or absence of
RanQ69L-GTP. Proteins bound to the beads were eluted and analyzed by 15% denaturing SDS-PAGE and silver staining. M, molecular weight protein
markers; lane 1, beads only + HSE; lane 2, Tnp3 + HSE + RanQ69L-GTP; lane 3, Tnp3 + HSE without RanQ69L-GTP. The arrow points to the ,20 kDa
tRNA band. (B) Nucleic acids were purified from the same fractions, analyzed by 15% denaturing PAGE and visualized following staining with
SYBRgold. Lane M, 10 bp ladder; Lane 1, total RNA from 293T cells; Lane 2, small RNA fraction from 293T cells; Lane 3, in vitro synthesized control
tRNA; Lane 4, same tRNA x3; Lane 5, HSE; Lane 6, Tnp3 + HSE + RanQ69LGTP; Lane 7, Tnp3 + HSE without RanQ69LGTP.
doi:10.1371/journal.ppat.1002194.g004
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Xpo-t is more sensitive to disruptions of the T-loop tertiary
structure then Tnp3. Intriguingly, swapping the G2 anticodon
sequence from lysine to aspartate (m22) inhibited tRNA binding to
Tnp3 but swapping to glutamate (m20) did not (Figure 6 and
Table 1). Overall these results indicated that substantial disrup-
tions of the tRNA tertiary structure impair Tnp3 binding, and that
the anticodon may be involved in recognition of Tnp3. These
findings also suggest that Tnp3 selectively binds tRNAs lacking a
mature 39CCA end, in contrast to Xpo-t where the intact 39CCA
tail is required for efficient interaction – an observation which
reinforces the idea that Tnp3 and Xpo-t have different
requirements for tRNA recognition.
Domains of Tnp3 involved in tRNA binding and export
To map the Tnp3 domains important for tRNA binding,
several N- and C- terminal Tnp3 deletion mutants were generated
and tested in pull down assays using equimolar amounts of tRNAs
and Tnp3 for cross-comparison (Figure 7). A deletion in the first
355 N-terminal residues of Tnp3 significantly inhibited binding to
RanGTP, in agreement with a previous study [39], and to tRNAs.
An even greater loss of tRNA binding was observed when the first
443 N-terminal residues of Tnp3 were deleted (Figure 7B).
Unfortunately, further N-term Tnp3 deletion mutants were poorly
soluble and could not be tested. Nonetheless, these results clearly
showed that a critical RanGTP binding domain was located
Figure 5. Binding of tRNAs to Tnp3 is influenced by the 39 CCA end. (A) Left panel, pull-down assays with GST-Tnp3 and G2 tRNA specie or
mutant G2 (m2) visualized by silver staining. Middle panel, pull down assays were performed with the m2 tRNA mutant or another G2 variant with a
complete 39 CCA end (m2a) (Table 1). Right panel, pull down assays with GST-Xpo-t or GST-Tnp3 and the m2a tRNA variant in the presence or
absence of RanGTP. The (-) symbol at the bottom of the panels indicates that RanGDP was added in place of RanGTP. (B) ImageJ quantification of pull
down assays shown in A. Values are expressed as ratio of recovered versus input tRNAs. (C) tRNA titration curves following SDS-PAGE and silver
staining.
doi:10.1371/journal.ppat.1002194.g005
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within the first 355 N-terminal residues of Tnp3, with residual
binding up to the first 443 N-terminal residues, and that binding of
RanGTP was important for tRNA recognition.
Two C-terminal Tnp3 deletion mutants were generated,
DC880 and DC825. Pull down assays with these two mutants
showed that binding of tRNA was mainly dependent on residues
between 825 and 880 of Tnp3 (Figure 7B – right panel).
Interestingly, the DC880 and DC825 Tnp3 mutants lost some
affinity for RanGTP, suggesting that Tnp3 may form a ternary
complex similar to the one recently described for Xpo-t, in which
RanGTP makes contact with the C-term of Xpo-t [36]. These
results are also consistent with the pull down results obtained using
viral tRNAs (Figure 3C and Figure 3D)
Export of tRNAs from the nucleus is a quality controlled
process, whereby Xpo-t selectively binds fully mature tRNAs
suitable for protein translation [34,35]. It was therefore surprising
to find that Tnp3 might be an export factor for defective tRNAs
lacking a complete 39 CCA end, which hinted at the possibility
that a parallel tRNA export pathway might exist in mammalian
cells. To examine if Tnp3 could indeed export these tRNA species,
an export assay was devised in permeabilized HeLa cells by
adapting the classical nuclear import assay [40] (Figure 8A). To
this end, HeLa cells were permeabilized by digitonin and a
standard nuclear import assay was carried out first in the presence
of purified and fluorescently labeled tRNAs (G2) and an energy
regenerating system. After 10 minutes incubation at 37uC to allow
tRNA nuclear accumulation [15], cells were washed and
incubated for a further 10 minutes at 37uC in the presence or
absence of recombinant Tnp3, an energy regenerating system and
the Ran system. Following this second incubation, cells were
washed, fixed and analyzed by confocal microscopy. A tRNA
export receptor should reduce the fluorescent signal from pre-
loaded nuclei and relocate tRNAs to the cytoplasmic side where
they are washed out. This modified assay was initially tested with
Xpo-t and provided an excellent readout for tRNA export
(Figure 8B).
In the export assay, addition of Tnp3 clearly reduced the
nuclear fluorescent intensity compared to controls and the effect
was specific because it was observed only in the presence of the
Ran system (Figure 8B). The reduction in the fluorescent signal
could not be explained by contamination of the protein
preparation with RNAse because it was not observed upon
addition of the individual components (Figure 8B, 8C). Moreover,
the export activity of the DN355, DN443 and DC825 Tnp3
deletion mutants correlated with their affinity for RanGTP and
tRNAs as detected in pull down assays (Figure 8B, 8C). We found
that the fluorescent signal was reduced in both nuclei and
cytoplasm, presumably because tRNAs in complex with Tnp3
were more soluble and could be more easily removed from the
cytoplasmic remnants of permeabilized cells by washing. These
results confirmed that Tnp3 is a RanGTP-dependent export factor
for some tRNAs species lacking a complete 39 CCA end. To test if
endogenous viral tRNAs were also exported by Tnp3, we
extracted tRNAs from purified viral particles and used them in
the export assay. Similarly to the in vitro synthesized G2 tRNA,
endogenous viral tRNAs were also exported by Tnp3 in the
presence of the Ran system (Figure 9).
HIV-1 CA is an important determinant for Tnp3 activity
In pull down assays with purified HIV-1 vector we found that
Tnp3 bound to CA, suggesting that it is an important target for
Tnp3 function. To further investigate the relevance of CA in
influencing susceptibility to Tnp3, we generated a panel of HIV-1
vectors with mutations in CA, which were previously shown to be
defective for infection at a post-nuclear entry step [11] and
examined their dependence on Tnp3 in stable HeLa Tnp3 KD
cells (Figure 10). The N74D point mutant, which is independent of
Tnp3 for infection [14] was tested in parallel. The T54A and the
T54A/N57A capsid mutant HIV-1 vectors showed substantially
reduced infectivity compared to wild type virus, however they
were also less dependent on Tnp3 for infection (Figure 10). We
also tested the A105S mutation, which conferred resistance to the
antiretroviral compound Coumermycin-A1 [41]. Interestingly,
Coumermycin-A1 was shown to inhibit HIV-1 integration [41],
similarly to the phenotype observed in Tnp3 KD cells, suggesting
that the compound and Tnp3 may act on same pathway. The
A105S mutant vector maintained near-wild type infectivity and
was also clearly less dependent on Tnp3 for infection. Of all
mutant vectors the N74D was the least dependent on Tnp3 for
infection and maintained normal infectivity (Figure 10). Similar
results were obtained using an HIV-1 vector bearing the gp120
envelope (Figure S4). These results confirmed that CA is an
important target of Tnp3 [14,19].
Tnp3 is an export factor for CA
Next we examined what the functional significance of the
interaction between CA and Tnp3 might be. The pull down assays
showed that Tnp3 binding to CA was stronger in the presence of
RanGTP. We therefore asked if Tnp3 was required for the export
of capsid from the nucleus of infected cells. We could not detect
accumulation of recombinant HIV-1 CA into the nucleus of
permeabilized cells, precluding the use of the nuclear export assay
in this case. Therefore, control and stable Tnp3 KD cells were
transduced at an MOI of 0.5 with the HIV-1 vector (Figure 11A),
Table 1. tRNA mutants generated and their characteristics.
Mutant name mutation mutation effect
G2 G2 WT Lysine 1,2 without CCA at 39 end
m2 G2+TTT G2 with TTT at 39 end
m2a +CCA inhibited in nuclear import
m5 U55A disruption of T-loop/D-loop pairing
m6 G18U/U55G Functional revertant of m5
m10 U54A T-loop point mutation with partial disruption of T-loop structure
m20 Lys-.Glu anticodon swap from Lysine to Glutamate
m22 Lys-.Asp anticodon swap from Lysine to Aspartate
doi:10.1371/journal.ppat.1002194.t001
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fractionated into nuclear and cytoplasmic fractions 16 hours post-
infection and the distribution of CA in each fraction was examined
by Western blot (Figure 11B). A relatively low MOI was used
because control and Tnp3 KD cells maintained a clear phenotype
with respect to HIV-1GFP infection in these conditions. Following
fractionation, CA was detected in the nuclear fraction of Tnp3 KD
cells and, to a lesser extent, control cells, whereas cytoplasmic CA
was significantly less abundant in Tnp3 KD than control cells
(Figure 11E). The biological significance of this result was
confirmed using an HIV-1 vector bearing the N74D mutation in
CA, which is the least dependent on Tnp3 for infection [14]
(Figure 11B, 11C). The N74D mutant virus did not appear to
accumulate CA in the nuclei in either control or Tnp3 KD cells
(Figure 11B). The ratio of nuclear to cytoplasmic CA was
significantly higher in KD than control cells infected with wild
type virus but remained essentially unchanged in cells infected
Figure 6. tRNA structural requirements for binding to Tnp3. (A) schematic representation of the tRNA secondary structure (cloverleaf) with
the mutations generated. Nucleotide changes were introduced by site-directed mutagenesis into the G2 tRNA backbone. Mutation affecting the
overall tRNA 3D structure is shown in red; a revertant of this mutation is shown in blue; anticodon swaps are indicated in grey, 39 end additions are
shown in purple. (B) Pull down assays were performed in the presence or absence of Tnp3 and RanQ69L-GTP, as indicated. Eluted tRNAs and proteins
were analyzed by SDS-PAGE and silver staining and quantified by ImageJ software. Values are expressed as ratio of recovered versus input tRNAs. G2
tRNA was given an arbitrary value of 1. Values above 1 indicate the fold increase in binding and values below 1 indicate the fold decrease in binding.
Mean values 6 SD of three independent experiments are shown. (C) Same as panel (B) but the pull down assays were performed in the presence of
Xpo-t.
doi:10.1371/journal.ppat.1002194.g006
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with the N74D mutant (Figure 11D). A different intracellular
distribution of wild type and N74D CA was also observed by
immunofluorescence (Figure S5). In this case, however, we had to
increase the MOI by 10 fold to $5 to be able to see a specific
intracellular p24 signal, which resulted in an almost complete loss
of phenotype in Tnp3 KD cells relative to control cells upon
infection with the HIV vector.
To investigate if the temporal dynamics of nuclear accumu-
lation of CA coincided with that of integration, we performed a
time-course experiment in cells infected with the HIV-1GFP
vector. Trace amounts of CA could be detected 6 h post-
infection, then CA progressively accumulated into the nucleus of
Tnp3 KD cells at 14 h and 24 h post-infection (Figure 11F).
Significantly less CA was detected in the nucleus of control cells
14 h and 24 h post-infection compared to KD cells (Figure 11F).
In contrast, the N74D CA mutant was not found accumulating
into the nuclei of either control or Tnp3 KD cells (Figure 11F).
The timing of CA nuclear accumulation was consistent with the
dynamics of viral integration in single-cycle infection assays
[27,42], supporting the notion that Tnp3 promotes a matura-
tion step, possibly by displacing any CA and tRNAs still bound
to the PIC.
Discussion
The steps of the HIV-1 life cycle between nuclear import and
integration are incompletely understood, in part due to technical
challenges and in part because much of the relevant molecular cell
biology of nuclear transport, chromatin remodeling and nuclear
dynamics have been discovered more recently. Greater knowledge
of these early steps of HIV-1 infection will impact on the
development of drugs with novel mechanisms of action and will
shed light on more fundamental cellular processes. Here we have
found evidence for an unanticipated step in the HIV-1 life cycle
occurring in the nucleus of infected cells that depends on the
cellular factor Tnp3. Connected to this step, we have also found
evidence for a novel cellular pathway dedicated to tRNA
nucleocytoplasmic shuttling.
In our experimental conditions Tnp3 was mainly required for
efficient HIV-1 integration. This may appear to contradict
previous studies [18,20,21], however Brass et al. reported a
significant integration defect but did not show any data on nuclear
import in Tnp3 KD HeLa TZM-bl cells [18] and Ko¨nig et al.
reported a significant drop in the number of integrated proviral
copies in Tnp3 KD 293 cells but no changes in 2LTRs [21]. Christ
et al. detected a modest (2–3 fold) block to 2LTR circular DNA
formation in Tnp3 KD HeLaP4 cells but observed a substantially
greater defect in viral integration [20]. Although presently we do
not exclude some effect on HIV-1 nuclear entry, we can however
conclude that integration is indeed an independent and important
step blocked in cells depleted of Tnp3.
Tnp3, nucleocytoplasmic shuttling of tRNAs and HIV-1
infection
Tnp3 was previously shown to bind to HIV-1 IN [20], which
provided an attractive explanation for the infectivity defect
observed in Tnp3 KD cells. However the physiological relevance
of the Tnp3/IN interaction remains uncertain, and the ability of
Figure 7. Tnp3 domains required for tRNA binding. (A) Schematic representation of the Tnp3 mutant constructs. (B) Pull down assays in the
presence of the indicated Tnp3 mutants, RanQ69L-GTP and G2 tRNA. Eluted proteins and tRNAs were analyzed by 15% SDS-PAGE and silver staining.
Smaller bands ,100 kDa are degradation impurities of Tnp3. Molecular weights (kDa) are shown on the left. ImageJ quantification of tRNA band
intensity is shown below each panel. (C) tRNA titration curves following SDS-PAGE and silver staining.
doi:10.1371/journal.ppat.1002194.g007
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Figure 8. Tnp3 is an export receptor for certain tRNA species. (A) Schematic representation of the nuclear export assay. Following cell
permeabilization, a nuclear import step is performed with fluorescently labeled tRNAs and the energy regenerating system. Once tRNAs accumulated
into the nucleus, cells are washed and a second incubation is performed in the presence of Tnp3, the Ran system and the energy system. Samples are
washed and analysed by confocal microscopy. Loss of fluorescence relative to control without Tnp3 indicated tRNA export. (B) Nuclear export of
Tnp3 Promotes HIV Integration
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Tnp3 to support HIV-1 infection mainly maps to CA [14,19].
Therefore we have taken an unbiased approach and performed
pull down assays to examine which components bind to Tnp3 in
the context of a mature viral particle. We detected binding of
Tnp3 to CA and viral tRNAs and, to our surprise, the affinity of
the interaction was greater in the presence of RanGTP (Figure 3).
Tnp3 is a nuclear import receptor for some serine-arginine rich
(SR) proteins, such as the splicing factor ASF and the human
papilloma virus-5 (HPV-5) E2 protein, which are released upon
RanGTP binding [39,43]. The observation that Tnp3 bound viral
tRNAs better in the presence of RanGTP suggested that it has
both nuclear import and nuclear export activity, depending on the
cargo. Other examples of this dual activity include importin 13
[44], exportin 4 [45,46] and Mtr10p [47,48], the hortologue of
Tnp3 in S. cervisiae. Tnp3 bound and exported some cellular
tRNAs as well as in vitro synthesized tRNAs lacking the 39 CCA
end. In this respect Tnp3 differs from Xpo-t, which binds
preferentially mature tRNAs with a complete 39 CCA end
[34,35,36]. These differences are most likely related to function:
Xpo-t is the main nuclear export receptor for mature tRNAs that
participate in protein translation, whereas Tnp3 appears more
likely to be involved in nuclear export of ‘‘defective’’ tRNAs. Tnp3
may be more similar to exportin 5 (exp5), which has more relaxed
structural requirements, recognizing and exporting different
double stranded RNAs, including tRNAs and miRNAs
[49,50,51,52,53].
Recent evidence showed that regulation of the tRNA retrograde
pathway is more complex than anticipated in S. cervisiae [16,54,55].
Whereas active nuclear import of tRNAs is constitutive, export of
tRNAs is regulated by availability of nutrients and inorganic
phosphates [56,57]. At least two parallel tRNAs export pathways
have been detected: one for the initial and subsequent export of
mature tRNAs, mediated by Los1p (the yeast hortologue of Xpo-
t), and a secondary export pathway, mainly mediated by Msn5, the
yeast hortologue of exportin 5 [58,59]. A similar scenario might be
present in human cells, whereby several parallel tRNA export
pathways serve different purposes. Although Mtr10p is implicated
in tRNA nuclear import in yeast [54,59], Tnp3 appears to be
mainly implicated in export of ‘‘defective’’ tRNAs in human cells.
Future work will elucidate the basis for this difference and if
additional co-factors participate in the tRNA shuttling process in
human cells. It is noteworthy that, in human cells, we have
observed energy-dependent nuclear accumulation primarily of
defective tRNAs lacking a complete 39 CCA end [15]. However,
whereas nuclear import of defective tRNAs may serve as a quality
control process by withdrawing such tRNAs from the protein
synthesis machinery, it is less clear at present why defective tRNAs
should also be exported from the nucleus of human cells. One
possibility is that defective tRNAs serve specific purposes, distinct
from protein translation. Supporting this hypothesis, there is
growing evidence showing that truncated or fragmented tRNAs
are specifically generated in mammalian cells and contribute to the
fluorescently–labelled G2 tRNAs (,100 ng each assay) in permeabilized HeLa cells in the presence of an energy-regenerating system (E), the Ran
system (R) and 1 mM of the indicated recombinant proteins. (C) Quantification of tRNA nuclear export. Images acquired by confocal microscopy were
analyzed by MetaMorph software version 4.5r4 and the total nuclear fluorescence divided by the number of cells per field. Bars represent the mean
fluorescence per nucleus 6 average deviation of two independent experiments. At least 100 cells were counted per experiment.
doi:10.1371/journal.ppat.1002194.g008
Figure 9. Tnp3 is an export factor for tRNAs incorporated into HIV-1 particles. (A) Viral tRNAs were isolated from purified HIV-1 particles (as
shown in Figure 3A), fluorescently labeled and used (,100 ng each assay) in the nuclear export assay as described in Figure 8 in the presence of an
energy-regenerating system (E), the Ran system (R) and 1 mM Tnp3. (B) Images acquired by confocal microscopy were analyzed by MetaMorph
software version 4.5r4 and the total nuclear fluorescence divided by the number of cells per field. Bars represent the mean fluorescence per nucleus
6 average deviation of two independent experiments. At least 100 cells were counted per experiment.
doi:10.1371/journal.ppat.1002194.g009
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regulation of protein synthesis, cell division and cell growth
[60,61,62,63,64]. Hence shuttling truncated tRNAs in and out of
the nucleus may have a fundamental biological function, quite
separate from HIV-1 infection. Another possibility is that shuttling
to a different cellular compartment signals that a defective tRNA
must be repaired.
Tnp3 binding to tRNAs was influenced by structural features
such as the lack of the complete 39 CCA tail, similar to tRNA
nuclear import in human cells [15], suggesting that the two
processes may be linked. Similar structural requirements for tRNA
retrograde transport on the one hand and Tnp3-mediated tRNA
nuclear export on the other hand as well as the involvement of CA
proteins in both processes [14,15] point to a common pathway of
which import and export may be two sides of the same coin.
It may seem counter-intuitive for HIV-1 to depend on defective
tRNAs for replication. However in metabolically active cells such
as chick embryo fibroblasts, the rate of tRNA synthesis has been
estimated at ,2.46105 molecules/min/diploid genome, with a
steady state value of ,109 tRNA molecules/diploid genome [65].
The tRNA half-life in dividing cells ranges between 50 h to 60 h
[65,66]. Importantly, the 39 CCA end is the most exposed portion
of the tRNA molecule and the most sensitive to a variety of
nucleases because it is single stranded. Therefore, the rate of tRNA
molecules being hydrolyzed at the 39 CCA end is likely to be very
high yet steady state levels of tRNAs with defective ends are by far
lower than normal tRNAs. The simplest explanation for this is that
tRNA repair/degradation mechanisms, which presumably include
tRNA shuttling, are extremely efficient. Therefore HIV-1 may in
fact have evolved to use one of the most efficient cellular trafficking
pathways available.
Tnp3 modulates nuclear ‘‘uncoating’’
In addition to tRNAs, Tnp3 also bound HIV-1 CA in pull down
assays. The strength of this interaction was greater in the presence
of RanGTP, suggesting that CA may be an export cargo for Tnp3.
The permeabilized cell assay could not be used to investigate this
possibility because we could not detect nuclear import of
recombinant CA. We therefore examined the nucleo-cytoplasmic
distribution of CA after acute infection of Tnp3 KD and control
cells. Remarkably, Tnp3 KD cells contained lower amounts of
cytoplasmic CA and relatively greater amounts of nuclear CA
compared to control cells. We also detected reduced levels of total
(nuclear + cytoplasmic) CA in Tnp3 KD cells compared to
controls. The reason for this is unclear but CA retained into the
nucleus due to lack of Tnp3 may be targeted for rapid degradation
in dividing cells, similarly to other nuclear factors [67]. A time
course experiment showed that the dynamics of CA nuclear
accumulation appear to overlap with that of HIV-1 integration in
single cycle assays [27,42]. The simplest interpretation of this
result is that Tnp3 exports CA from the nucleus of infected cells.
The biological significance of this result is supported by
experiments with the N74D CA mutant HIV-1 vector. Among
the CA mutants tested, the N74D was the least dependent on
Tnp3 for infection, suggesting that either the N74D CA was shed
before nuclear entry or that it could exploit different factors for its
export, becoming more promiscuous. In pull down assays, we have
detected binding of Tnp3 to the N74D CA mutant (Figure S5). We
have also detected CA in the nuclei of control cells 16 h post-
infection by immunofluorescence whereas mutant N74D CA
localized mostly outside the nuclei or at the nuclear envelope
(Figure S5). The time course experiment shown in Figure 11 also
suggested that N74D CA does not enter into the nucleus, at least
for up to 24 h post-infection. Therefore it appears that the N74D
CA is shed before nuclear entry of the RTC/PIC, making Tnp3
unnecessary. It will be interesting to see if such a premature loss of
CA impacts on other downstream events.
Accumulating evidence indicates that HIV-1 CA impacts on
post-nuclear entry events [9,17,68]. Furthermore, a functional link
Figure 10. CA is an important determinant for HIV-1 dependence on Tnp3. Infection assays were performed in stable HeLa Tnp3 KD cells or
control cells expressing a scrambled shRNA using HIV-1GFP vectors bearing the indicated mutation in CA. Viral stocks were normalized for RT activity
and different volumes used for titrations. Infected cells were analysed by flow cytometry 48 hours post-infection. Note that the T54A and T54A/N57A
have ,20 fold lower infectivity than wild type virus. Data are representative of at least 3 independent experiments.
doi:10.1371/journal.ppat.1002194.g010
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between HIV-1 CA and integration has been recently described
using a chemical genetic approach, whereby the small molecule
Coumermycin-A1 impaired integration by targeting HIV-1 CA
[41]. Interestingly, the A105S CA mutation made the virus
insensitive to this block [41]. It is remarkable that the same
mutation also makes HIV-1 independent of Tnp3 for infection,
suggesting that Coumermycin-A1 and lack of Tnp3 perturb the
same pathway. Moreover, the A105T mutation in CA was
shown before to influence HIV-1 post-entry events in a
cyclophilin A (CypA) dependent way [68]. However the
mechanism by which CA impacts on post-nuclear entry events
and integration is poorly understood. One hypothesis is that
insufficient uncoating of the viral core in the cytoplasm may
affect downstream events by making the pre-integration
complex too bulky or unsuitable to bind specific host factors.
Alternatively, following uncoating in the cytoplasm, some CA
may remain bound to the pre-integration complex and help
HIV-1 negotiate through the NPC [14,69]. In this case, some
CA is likely to remain bound to the PIC after nuclear
translocation. Indeed the presence of CA associated with the
PIC inside the nucleus can be inferred from previous studies in
which the restriction factors Fv-1 and members of the TRIM
protein family were fused to CypA. The resulting fusion proteins
maintained their specific ability to bind CA yet restricted HIV-1
at a post-nuclear entry step [70,71].
We propose a unifying hypothesis. Our results show that Tnp3
promotes the export of certain viral components from the nucleus
of infected cells and that efficient HIV-1 integration depends on
this activity. Therefore, several uncoating steps may be necessary
for HIV-1 infection. The main uncoating step likely occurs in the
Figure 11. Tnp3 affects the nucleo-cytoplasmic distribution of CA. (A) Control (Scr) and Tnp3 KD HeLa cells were infected with WT HIV-1GFP
vector and analyzed by flow cytometry 24 hours later; mean values 6 SD of three independent experiments are shown. (B) Infected cells were
fractionated into nuclear and cytoplasmic fractions 16 hours post-infection and each fraction was analyzed by Western blot. N+/K+ ATPase (ATPase)
and DNA topoisomerase II (TopoII) were used to control the fractionation procedure. Data are representative of three independent experiments. (C)
Control (Scr) and Tnp3 KD HeLa cells were infected with the N74D mutant vector and analyzed by flow cytometry 24 hours later; mean values6 SD of
three independent experiments are shown. (D) Relative amount of CA detected by Western blot in nuclear and cytoplasmic fractions was quantified
by ImageJ; mean values 6 SD of three independent experiments are shown. (E) Relative amount of CA detected by Western blot in the cytoplasmic
fractions of Scr and Tnp3 KD cells was quantified by ImageJ; mean values 6 SD of three independent experiments are shown. (F) Time course of CA
nuclear accumulation. Cells were transduced with the HIV-1GFP vector at an MOI of 0.5 and fractionated at the indicated time points. Fractions were
analysed by Western blotting with anti-CA antibodies. Virus input was normalized for infectivity in HeLa cells, hence the higher amount of N74D CA
detected at the 6h time point. Similar results were obtained in another independent experiment.
doi:10.1371/journal.ppat.1002194.g011
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cytoplasm, presumably starting shortly after initiation of reverse
transcription [6,10], and the last uncoating step occurs inside the
nucleus. To permit efficient nuclear entry, some CA and tRNAs
must remain associated with the viral complex [14,15] but once
their function is exhausted, these same elements must be displaced
to facilitate integration (Figure 12). We propose that Tnp3 is the
displacing factor. The requirement for RanGTP ensures that
Tnp3 binds to the viral elements with greater affinity after the PIC
has entered into the nucleus, where RanGTP concentration is
highest [24]. PICs that have not ‘‘matured’’ may fail to interact
with host factors present in the nucleus, impairing integration both
quantitatively and qualitatively. Our model is supported by recent
evidence indicating that depletion of Tnp3 results in an aberrant
pattern of HIV-1 integration [72].
Materials and Methods
Ethics statement
Blood was obtained from healthy volunteers after written
informed consent according to the approved protocol of the UCL
Figure 12. A model of the role of Tnp3 in HIV-1 infection. After virus entry into the cell, the viral core is disassembled but some capsid proteins
(light blue dots) remain associated with the RTC. A complex is formed between capsid proteins, tRNAs and presumably one or more host cell factors
to engage with the tRNA retrograde transport pathway, leading to nuclear import of the RTC/PIC. CA associated to the RTC/PIC may also play a role in
nuclear import by binding to components of the NPC, as well as other factors that may associate with IN. Once inside the nucleus, the PIC must
complete the uncoating process by removing any remaining capsid proteins and tRNAs, which are detrimental to integration. Tnp3, in complex with
RanGTP, carries out this step.
doi:10.1371/journal.ppat.1002194.g012
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Ethics Committee ref. 0335/001 or from buffy coats obtained
from the NHS National Blood Service according to Governmental
ethics regulations.
Cell culture, virus production and infection
HUES-2 hES cells [73] were differentiated to monocytes via
embryoid body formation followed by directed differentiation in
Advanced DMEM, supplemented with 10% FCS, 100 ng/mL M-
CSF (R&D), 25 ng/mL IL-3 (R&D), 2 mM l-glutamine (Invitrogen
GIBCO), 100 U/mL penicillin and 100 mg/mL streptomycin
(Invitrogen GIBCO), and 0.055 mM b-mercaptoethanol (Invitrogen
GIBCO). Monocytes emerging into the supernatant after 3–6 weeks
were harvested and further differentiated to macrophages for 1 week
at a density of 1.56105 cells/cm2, in culture medium consisting of
RPMI (Invitrogen GIBCO) supplemented with 10% FCS, 100 ng/
mLM-CSF (R&D), 2 mM l-glutamine (Invitrogen GIBCO), 100 U/
mL penicillin and 100 mg/mL streptomycin (Invitrogen GIBCO)
[25]. Macrophages were isolated from buffy coats from healthy
donors by standard Ficoll-Hypaque density centrifugation. Cells were
incubated at a density of 56104/well in a volume of 100 mL in 96 well
plates for 72 h in the presence of 20 ng/ml of GM-CSF before media
change and infection at day 5. HeLa and 293T cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco Labs, Paisley,
UK) supplemented with 10% foetal calf serum (FCS) (Helena
Bioscience, Newcastle, UK) and 2 mM glutamine at 37uC in 5%
CO2. Jurkat cells were grown in RPMI medium supplemented with
10% FCS at 37uC in 10% CO2. Supernatants containing HIV-1
pseudotyped with amphotropic envelope were collected from stable
producer cells [31], centrifuged at 3000 g for 10 mins, filtered
through a 0.45 mm filter and purified as described [15]. pHIVLAI-
Denv and HIV-1GFP vectors were made and purified as described
previously [2,26]. For HIV-1GFP plasmids pCSGW, pCMVDR8.2,
(expressing gag-pol) and pMD.G expressing VSV-G were used
[12,74,75]; pHIVLAIDenv was pseudotyped using plasmid pMD.G.
Reverse transcriptase (RT) activity was measured by the Lenti-RTTM
Activity Assay (Cavidi Tech, Uppsala, Sweden) following the
manufacturer’s instructions. For infections, HeLa cells were plated
onto 24 well plates at 36104/well, infected 24 hours later with serial
dilutions of viral stocks and analyzed by FACS from 24 hours to 2
weeks after infection. Jurkat cells were plated at 56105/ml in 48-well
plates, infected with serial dilutions of HIVGFP and analysed by FACS
48 hours later. For DNA analysis, Jurkat cells were plated at 56105/
ml in 6-well plates, infected at an MOI of 0.1 and DNA extracted
24 h, 48 h and 10 days later.
Depletion and rescue of Tnp3
Tnp3 was knocked down using two siRNAs; Tnp3-1 sense,
GCAGUGAUAUUUAGGCAUAUU, antisense, UAUGCCUA-
AAUAUCACUGCUU; Tnp3-2 sense, GUACCAAAACUAAC-
GAUGAAUU; antisense, UUCAUCGUUAGUUUUGUACUU
[18]. HeLa cells were plated in 6-well plates at 1.56105/well and
transfected with siRNAs and oligofectamine (Invitrogen) the
following day according to the manufacturer’s instructions. To
generate stable Tnp3 KD cells, Tnp3 oligonucleotides 59-CTA-
GTCGGCGCACAGAAATTATACTTCCTGTCATATAATT-
TCTGTGCGCCGTTTTT-39 and 59-GTACAAAAATCGGC-
GCACAGAAATTATATGACAG GAAGTATAATTTCTGTG-
CGCCGA-39 or scrambled oligonucleotides 59-CTAGTCGGCG-
CAGTCTAATTATACTTCCTGTCATATAATTAGACTGC-
GCCGATTTTT-39 and 59-GTACAAAAATCGGCGCAGTC-
TAATTATATGACAGGAAGTATAATTAGACTGCGCCGA-
39 [20] were annealed and cloned into pSIREN vector (Clontech).
The resulting vector was used for virus production and infection of
target HeLa, Jurkat and 293T cells. Differentiated macrophages
were transduced with a lentiviral vector bearing the same shRNA
expression construct. A silent mutation was introduced into the
human Tnp3 cDNA to make it resistant to shRNA targeting by
QuickChange II XL (Stratagene) following the manufacturer’s
instruction with primers C498A forward CGAATTGGAGC-
TAATCGGCGAACAGAAATTATAGAAGATTTG and C498A
reverse CAAATCTTCTATAATTTCTGTTCGCCGATTAGC-
TCCAATTCG. Four clones were confirmed by sequencing and
cloned into pCDNA3 to generate pTnp3-R for expression into
mammalian cells. pTnp3-R was used as a template to generate
DC825Tnp3-R by PCR using primers DC forward ATCATC-
GAATTCATGGAAGGAGCAAAGCCG and DC reverse AT-
CATCCTCGAGTCACACCTGTCCAATCAG. Clones were
confirmed by sequencing. For the rescue assay, 293T cells were
plated into 48-well plates at 26105/well and infected the next day
with serial dilutions of pSIREN shRNA-Tnp3 or pSIREN shRNA-
Scramble MLV vector. Forty-eight hours post-infection, cells were
transferred into 24-well plates and selected with 1 mg/ml puromy-
cin. Puromycin-resistant cells were plated into 6 well plates at 106/
well and transfected 24 h later with 1 mg and 2 mg Tnp3-R or
DC825Tnp3-R plasmids complexed with Fugene-6 (Roche). Cells
were incubated for 48 h, infected with the HIV-1 vector and
analyzed by FACS 24 h post-infection.
Generation, expression and purification of recombinant
proteins
The GST-Xpo-t expression plasmid was generated by PCR
from pQE30-Xpo-t [37] as a template using forward primer 59-
ATCGGATCCATGGATGAACAGGCTCTATTAG-39 and re-
verse primer 59-. ATCGAATTCTCAGGGCTTTGCTCTCTG-
39, and cloned into BamHI and EcoRI sites of pGEX-2T. GST-
Xpo-t and GST-Tnp3 (pGST-TRN-SR2 [39]) plasmids were
expressed in E. Coli strain BL21(DE3) by overnight incubation at
16uC on induction with 0.5 mM isopropyl ß-D-thiogalactoside.
The GST-fusion proteins were purified by using glutathione-
Sepharose beads and then dialyzed against binding buffer using a
50 kDa c/o membrane. Alternatively, GST was cleaved by
incubating for 16 h at 4uC with 15 U/mg Thrombin (Amersham
Biosciences) and eluted untagged proteins were dialyzed (50 kDa
c/o) in import buffer. Tnp3 deletion mutants were generated by
PCR with Pfu DNA polymerase using plasmid pGST-TRN-SR2
[39] as template and the following primers:
DN443 Tnp3 forward ATCGGATCCATGGCTGCTATAG-
CAAAGAG
DN534 Tnp3 forward ATCGGATCCATGGCTCAGCACT-
TTAATG
and reverse: CCGGAATTCTCATCGAAACAACCTGGTG
DC880 Tnp3 reverse CCGGAATTCTCATGGCAAACC-
TTTTAAGG
DC825 Tnp3 reverse CCGGAATTCTCACACCTGTCCAA-
TCAG
and Tnp3 forward ATCGGATCCATGGAAGGAGCAAAGC
PCR products were cloned into pGEX-2T using BamHI and
EcoRI, confirmed by sequencing and expressed in E. Coli strain
BL21(DE3) by overnight incubation at 16uC on induction with
0.5 mM isopropyl ß-D-thiogalactoside. The GST-fusion proteins
were purified by using glutathione-Sepharose beads and by gel
filtration using a Superdex 200 column. The components of the
Ran system and RanQ69L were expressed and charged with GTP
or GDP as previously described [30,76,77].
Preparation of 60S HSE and viral samples
The pellet from ,109 HeLa cells was washed once in
phosphate-buffered saline (PBS) and resuspended in 5 vols of
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hypotonic buffer (10 mM Hepes pH 7.9, 10 mM KCl, 1.5 mM
MgCl2, 1 mM DTT, 20 mg/ml aprotinin and leupeptin) on ice.
The supernatant was centrifuged at 3300 g for 10 min at 4uC,
resuspended in 5 vols of hypotonic buffer and incubated on ice for
10 min with gentle stirring. Cells were broken by Dounce
homogenization on ice and centrifuged at 3300 g for 15 min at
4uC. The supernatant was centrifuged at 7500 g for 20 min at 4uC
and then ultracentrifuged at 100, 0001 g for 4.5 h at 4uC. The
supernatant was passed through a glass wool filter and then
through a 0.45 mm filter. Samples were concentrated using
Vivaspin concentrator (Amersham) and ,3.8 mg of 60S HSE
was used in pull down assays. Pellets containing HIV-1 vector
were resuspended into 200 ml of binding buffer. To disrupt virus
particles, 160 ml purified viral stock was sonicated for 6 sec. at 40
output level in an Ultrasonicator Process machine and 50 ml were
used in pull down assays.
Pull down assays
Mutant tRNA clones were obtained by PCR using mutagenic
primers (see Table S1 and Table S2), generated by T7 polymerase
and purified as previously described [15].
Pull-down assays were performed with ,6.5 mg GST-Tnp3 or
GST-Xpo-t, 3 mg tRNAs, 14 mg RanQ69L-GTP in a final volume
of 30 ml binding buffer (50 mM Hepes pH 7.3, 200 mM NaCl,
2 mM Mg(Ac)2 and 10 mM GTP). The mix was incubated at 4uC
for 30 mins with gentle mixing then 20 ml equilibrated Glutathi-
one-sepharose 4B beads (GE Healthcare) were added and samples
incubated for a further 2 h at 4uC with continuous rotation.
Samples were washed with binding buffer (1 ml64 washes), mixed
with 30 ml 5x SDS-sample buffer and boiled for 10 mins, resolved
by 10% SDS-PAGE and visualized by silver staining following the
manufacturer’s instructions (Silver Staining Plus, BioRad). ImageJ
1.42q (NIH) was used to quantify the intensity and the total area of
the bands in silver stained gels following thresholding to optimize
linearity of the signal. Values of the pulled down bands were
normalized by the input bands in each sample.
Export assays
Import assays were performed with fluorescently-labelled
tRNAs as previously described [15,77] except that incubation of
permeabilized cells with tRNAs and the energy regenerating
system was at 37uC for 10 mins. Samples were washed 3 times in
import buffer (20 mM HEPES pH 7.3, 110 mM KAc, 5 mM
Mg(Ac)2, 0.5 mM EGTA, 250 mM sucrose) on ice then the export
mix was added (Tnp3 to 1 mM final concentration and 1x energy
mix and 1xRan mix in 30 ml import buffer) and samples incubated
at 37uC for 10 mins. Following three washes in import buffer,
samples were fixed in 2% paraformaldehyde in import buffer for
5 mins on ice, washed twice in import buffer and analyzed by
confocal microscopy. Quantitative analysis of fluorescent signal in
the nuclei was performed on confocal images by MetaMorph
software version 4.5r4 (Universal Imaging Corp., Molecular
Devices) as previously described [15].
Western blot
Rabbit polyclonal anti-importin 7 antibodies were previously
described [77], monoclonal antibody 3152C2a against Tnp3 was
purchased from Abcam (Cambridge, UK) and used 1/500 dilution
in TBST-T. Anti-p24/p55 monoclonal antibodies EH12E1 and
3D3 were obtained from the AIDS repository reagent programme
EVA centre for AIDS reagents, UK, mixed and used at 1/300
dilution. Anti-b-actin monoclonal antibody (AC-40, Sigma-
Aldrich) was used at a 1/10,000 dilution. Anti-rabbit and anti-
mouse IgG HRP-conjugated antibodies were purchased from
Jackson Laboratories (Bar Harbor, MN) and from Sigma
respectively. After SDS PAGE, the proteins were transferred
overnight to a PVDF membrane (Bio-Rad, Hercules, CA) in
transfer buffer pH 8.4 containing 0.01% SDS and 5% methanol
and probed with the primary antibodies for 1 h at room
temperature. HRP-conjugated secondary antibodies were used
diluted 1/3,000 in 10% non-fat milk. Chemiluminescence (ECL,
Amersham) was used to develop the blots as described by the
manufacturer. Autoradiography films were exposed for different
periods of time to ensure linearity of the signal.
Cell fractionation and detection of viral DNA
Approximately 106 HeLa cells were plated onto 10 cm plates.
The next day cells were infected at an MOI of 0.2–0.5 for 22–24
hours, trypsinized and fractionation was performed in the presence
of NP-40 as previously described [26,78]. For DNAse I digestion,
10 ml DNAse I beads (MoBiTec, Go¨ttingen, Germany) were
added to the fractionation buffer with 5 mM CaCl2 and incubated
at 4uC for 5 mins with rotation, followed by washes as previously
described. TaqMan qPCR was performed in an ABI Prism 7000
thermocycler as described [78]. For amplification of 2LTR
circular DNA, the same conditions were used with primers
2LTRqPCRF: 59-AACTAGAGATCCCTCAGACCCTTTT-39
and 2LTRqPCRRC: 59-CTTGTCTTCGTTGGGAGTGAA-
TT-39 and probe 59-FAM-CTAGAGTTTTCCACACTGAC-0-
TAMRA-39 [26]. Standards were prepared by PCR amplification
of DNA from acutely infected cells with primers 2LTRF 59-
GCCTCAATAAAGCTTGCCTGG-39 and 2LTRRC 59-TCC-
CAGGCTCAGATCTGGTCTAAC-39. The amplification prod-
uct was cloned into TOPO vector, amplified and confirmed by
sequencing. Detection of cyclophilin A cDNA was as described
[26]. Alu-LTR Taqman qPCR was carried out as previously
described [41] using primers ALU-forward, AAC TAG GGA
ACC CAC TGC TTA AG and LTR1-reverse, TGC TGG GAT
TAC AGG CGT GAG (for first round amplification) and ALU-
forward AAC TAG GGA ACC CAC TGC TTA AG, LTR2-
reverse, TGC TAG AGA TTT TCC ACA CTG ACT, ALU-
probe, FAMRA – TAG TGT GTG CCC GTC TGT TGT GTG
AC – TAM (for second round Taqman qPCR).
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Supporting Information
Figure S1 Tnp3 facilitates integration of HIV-1 in CD4+ T-cells.
(A) Jurkat cells were transduced with an MLV-based vector
delivering an shRNA expression construct targeting human Tnp3
mRNA. Cells were normalised by cell number and knockdown of
Tnp3 was examined by Western blotting. (B) HIVGFP vector was
used to transduce Tnp3-KD and wild type (WT) Jurkat cells. The
percentage of GFP-positive cells was determined by flow cytometry.
Average values6 SD of three independent experiments are shown.
Total DNA was extracted from infected cells at the indicated time
points and the amount of total linear viral DNA (C) and 2LTR
circular DNA (D) copies per 100 ng total DNA were determined by
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Taqman qPCR. (E) Diagram showing ratio of total linear viral
DNA to 2LTR circles. (F) The amount of integrated provirus
copies/100 ng total DNA in Tnp3-KD and WT Jurkat cells was
determined 10 days post infection by Alu-LTR Taqman qPCR.
Average values6 SD of three independent experiments are shown.
(JPG)
Figure S2 Nuclear viral DNA is protected from DNAse I
digestion. (A) Tnp3 KD cells were transduced at MOI of 0.5 with
HIV-1GFP and fractionated 24 h later in the presence of DNAse I
beads. Viral DNA in each fraction was measured by Taqman
qPCR. Average 6 SD of triplicate determinations are shown,
representative of two independent experiments. (B) HIV-1GFP
plasmid DNA was incubated in parallel with the same amount of
DNAse I beads used for the cell fractionation, re-purified and
subjected to Taqman qPCR.
(JPG)
Figure S3 Infection with VSV-G pseudotyped HIV LAIDenv is
impaired in Tnp3 KD HeLa cells. (A) Tnp3 KD and control
(scramble) cells were infected with two doses of HIV LAIDenv and
analyzed by FACS 24 h and 48 h post-infection. Data are
expressed as average percentage of infection relative to control
(scramble siRNA) 6 average deviation of two independent
experiments performed in duplicate. (B) Total viral DNA and
(C) 2LTRs circular viral DNA were quantified in Tnp3 KD and
control cells by Taqman qPCR 24 h and 48 h post-infection.
Average values 6 average deviation of two independent
experiments are shown, which were each performed in duplicate.
(JPG)
Figure S4 The viral envelope does not significantly influence
susceptibility to Tnp3 KD. Polyclonal populations of TZM-bl cells
stably expressing a control shRNA or a shRNA targeting Tnp3
were transduced at an MOI of 0.03 with HIV-1GFP bearing the
VSV-G or gp120 envelopes and analyzed by flow cytometry 48
hours later. Average values 6 SD of three independent
experiments are shown.
(JPG)
Figure S5 HIV-1 capsid is detected in the nucleus at 16 hours
post-infection but the mutant N74D capsid remains cytoplasmic.
(A) HeLa cells stably expressing a scrambled shRNA control were
seeded onto glass coverslips and either left untreated (lower panel),
or infected with WT virus (upper panel) or N74D mutant virus
(middle panel) at an MOI of 5 for 16 h at 37uC. The cells were
then washed to remove virus, fixed with formaldehyde, permea-
bilized with methanol and stained with mouse monoclonal
antibody specific for HIV-1 Gag p24/p55 (clone EH12E1 donated
by Dr. R.B. Ferns and Dr. R.S Tedder and obtained from the
Center for AIDS Reagents, National Institute of Biological
Standards and Control, UK) followed by an anti-mouse IgG1-
Alexa543 conjugated secondary antibody (Invitrogen). Coverslips
were mounted with ProLong Gold antifade containing DAPI
(Invitrogen) and visualized using a Leica SP2 confocal microscope.
Image processing was performed using Metamorph v7 and
Photoshop. Images are single, /xy/ sections taken through the
middle of the cell and the right hand panel shows a higher
magnification image of the cells indicated with arrows. Scale bars
are 5 mm. (B) Pull down assay with GST-Tnp3 in the presence or
absence of RanQ69L-GTP and purified HIV-1 vector bearing the
N74D mutation in CA. Viral tRNAs were detected by silver
staining and p24 CA (N74D) was detected by Western blot.
ImageJ quantification of pull down assays is shown in the bottom
panels. Values are expressed as ratio of input versus recovered
tRNAs.
(JPG)
Table S1 Sequences of the tRNA mutants used in pull downs
and export assays. The complete sequences of the tRNAs
generated by T7 polymerase are shown. Changes to the original
G2 template are highlighted in red and underlined.
(DOC)
Table S2 Sequences of the primers used to generate the tRNA
T7 template by PCR. The T7 promoter sequence is highlighted in
blue. Mutants m20 and m22 were generated in two separate
rounds of amplification. The forward primer sequences for the first
amplification round (1st) are given, the second amplification round
was primed with the G2 forward primer.
(DOC)
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